| Literature DB >> 24870949 |
Eun-Jung Rhee1, Min Kyung Lee1, Jong Dae Kim1, Won Seon Jeon1, Ji Cheol Bae2, Se Eun Park1, Cheol-Young Park1, Ki-Won Oh1, Sung-Woo Park1, Won-Young Lee1.
Abstract
BACKGROUND: Recent studies report the importance of metabolic health beyond obesity. The aim of this study is to compare the risk for diabetes development according to different status of metabolic health and obesity over a median follow-up of 48.7 months.Entities:
Mesh:
Year: 2014 PMID: 24870949 PMCID: PMC4037196 DOI: 10.1371/journal.pone.0098369
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of baseline characteristics between the groups divided by metabolic health and obesity status.
| N = 6,748 (%) | Total | MHNO | MHO | MUHNO | MUHO |
|
| N = 3055 (45.3) | N = 762 (11.3) | N = 1464 (21.7) | N = 1467 (21.7) | |||
| Age (years) | 43.0±4.8 | 42.8±4.9a | 43.1±4.6a,b,c | 43.4±4.9b,d | 43.1±4.5c,d | <0.01 |
| Gender: men (%) | 4958 (73.5) | 1752 (57.3) | 599 (78.6) | 1235 (84.4) | 1372 (93.5) | <0.01 |
| FBS (mg/dL) | 95.3±8.5 | 91.9±6.9 | 93.6±6.4 | 98.5±8.7 | 100.1±8.8 | <0.01 |
| AST (IU/L) | 23.8±8.8 | 21.9±7.0 | 24.3±8.4 | 23.8±9.2 | 27.2±10.7 | <0.01 |
| ALT (IU/L) | 26.0±17.5 | 20.0±11.3 | 27.7±15.7a | 27.4±19.9a | 36.3±20.9 | <0.01 |
| BUN (mg/dL) | 14.0±3.3 | 13.7±3.3 | 14.7±3.5a | 14.0±3.3 | 14.5±3.4a | <0.01 |
| Serum creatinine (mg/dL) | 1.1±0.2 | 1.02±0.15 | 1.09±0.14 | 1.10±0.14 | 1.14±0.14 | <0.01 |
| TC (mg/dL) | 193.7±32.2 | 187.3±30.6 | 198.7±29.9 | 195.4±32.5 | 202.9±33.5 | <0.01 |
| Triglyceride (mg/dL) | 137.0±84.9 | 93.6±36.3 | 114.0±44.0 | 177.5±94.0 | 198.8±104.7 | <0.01 |
| HDL-C (mg/dL) | 51.4±11.6 | 56.7±11.7 | 53.1±0.2 | 46.3±9.4 | 44.8±8.0 | <0.01 |
| LDL-C (mg/dL) | 112.4±27.0 | 107.5±25.9 | 119.8±25.3a | 112.6±26.9 | 118.7±27.8a | <0.01 |
| HbA1c | 5.37±0.3 | 5.33±0.3 | 5.36±0.3a | 5.39±0.4a | 5.46±0.4 | <0.01 |
| Fasting insulin (IU/L) | 8.6±3.2 | 7.3±2.3 | 8.6±2.6a | 8.8±3.1a | 10.9±3.9 | <0.01 |
| Hs-CRP (mg/dL) | 0.12±0.3 | 0.09±0.3 | 0.13±0.3 | 0.11±0.2 | 0.16±0.4 | <0.01 |
| Body weight (kg) | 67.7±10.8 | 60.8±8.2 | 75.1±7.4 | 66.7±7.2 | 79.0±7.6 | <0.01 |
| BMI (kg/m2) | 23.9±2.8 | 22.0±1.8 | 26.5±1.2 | 23.2±1.4 | 27.2±1.8 | <0.01 |
| Systolic BP (mmHg) | 113.6±14.3 | 107.9±11.8 | 112.6±11.3 | 118.0±14.6 | 121.8±14.8 | <0.01 |
| Diastolic BP (mmHg) | 75.8±10.0 | 71.6±8.2 | 75.6±8.1 | 78.5±9.7 | 81.9±10.4 | <0.01 |
| Waist circumference (cm) | 80.9±9.0 | 75.2±7.4 | 87.7±5.9 | 80.9±6.1 | 90.0±5.6 | <0.01 |
| Lean mass (kg) | 48.8±8.3 | 44.6±7.6 | 52.4±7.4 | 49.0±6.7 | 55.2±6.2 | <0.01 |
| Skeletal muscle index | 72.1±5.1 | 73.1±5.3 | 69.5±5.1a | 73.4±4.3 | 69.9±4.1a | <0.01 |
| Body fat mass (kg) | 16.1±4.6 | 13.6±3.3 | 19.7±3.5 | 14.8±2.8 | 20.7±4.0 | <0.01 |
| Percent body fat (%) | 23.7±5.4 | 22.5±5.5a | 26.5±5.3b | 22.4±4.5a | 26.2±4.3b | <0.01 |
| HOMA-IR | 2.0±0.8 | 1.67±0.5 | 1.99±0.6 | 2.15±0.8 | 2.71±1.0 | <0.01 |
| Subjects with IFG (%) | 1845 (27.3) | 301 (9.9) | 79 (10.4) | 712 (48.6) | 753 (51.3) | <0.01 |
| Diabetes development (%) | 277 (4.1) | 27 (0.9) | 14 (1.8) | 79 (5.4) | 157 (10.7) | <0.01 |
| Subjects who have ever smoked (%) | 3632 (53.8) | 1242 (41.4) | 433 (57.7) | 923 (63.7) | 1034 (71.2) | <0.01 |
| Alcohol drinking (%) | 599 (8.9) | 215 (7.0) | 82 (10.8) | 148 (10.1) | 154 (10.5) | <0.01 |
| Regular exercise (%) | 1246 (18.5) | 645 (21.1) | 158 (20.7) | 217 (14.8) | 226 (15.4) | <0.01 |
| Antihypertensive medication (%) | 353 (5.2) | 51 (1.7) | 19 (2.5) | 103 (7.0) | 180 (12.3) | <0.01 |
| Education status (%) | 0.056 | |||||
| No education | 14 (0.2) | 10 (0.3) | 0 (0) | 2 (0.1) | 2 (0.1) | |
| Elementary school | 117 (1.7) | 54 (1.8) | 13 (1.7) | 28 (1.9) | 22 (1.5) | |
| Middle school | 66 (1.0) | 34 (1.1) | 12 (1.6) | 11 (0.8) | 9 (0.6) | |
| High school | 1588 (23.5) | 771 (25.2) | 166 (21.8) | 343 (23.4) | 308 (21.0) | |
| Technical college | 573 (8.5) | 260 (8.5) | 63 (8.3) | 120 (8.2) | 130 (8.9) | |
| High than university | 4390 (65.1) | 1926 (63) | 508 (66.7) | 960 (65.6) | 996 (67.9) |
MHNO, metabolically healthy non-obese; MHO, metabolically healthy obese; MUHNO, metabolically unhealthy non-obese; MUHO, metabolically unhealthy obese; FBS, fasting blood sugar; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; BUN, blood urea nitrogen; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; hs-CRP, high-sensitivity C-reactive protein; BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model assessment index - insulin resistance, IFG, impaired fasting glucose.
* P values for one-way ANOVA test. a,b,c,d,e Same letters denote no significant differences between the designated groups in post-hoc analyses. Otherwise, groups showed significant differences between each groups with post-hoc analyses.
Values for waist circumference were available only in 2900 subjects due to the inconsistency in measurement method.
Subjects who have ever smoked more than 5 packs of cigarettes.
Comparisons of baseline prevalence of metabolic components between the groups divided by metabolic health and obesity status.
| Total | MHNO | MHO | MUHNO | MUHO |
| |
| N = 3055 | N = 762 | N = 1464 | N = 1467 | |||
| High blood pressure | 1758 (26.1) | 244 (8.0) | 104 (13.6) | 608 (41.5) | 802 (54.7) | <0.01 |
| High TG | 2147 (31.8) | 152 (5.0) | 96 (12.6) | 898 (61.3) | 1001 (68.2) | <0.01 |
| Low HDL-C | 3352 (49.7) | 793 (26.0) | 249 (32.7) | 1137 (77.7) | 1173 (80.0) | <0.01 |
| IFG | 1845 (27.3) | 301 (9.9) | 79 (10.4) | 712 (48.6) | 753 (51.3) | <0.01 |
| High HOMA-IR | 675 (10.0) | 24 (0.8) | 19 (2.5) | 199 (13.6) | 433 (29.5) | <0.01 |
MHNO, metabolically healthy non-obese; MHO, metabolically healthy obese; MUHNO, metabolically unhealthy non-obese; MUHO, metabolically unhealthy obese; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; HOMA-IR, homeostasis model assessment index - insulin resistance.
Figure 1Comparisons of prevalence of metabolic components according to the four groups divided by baseline metabolic health and obesity status.
Hazard ratio for incident diabetes according to baseline metabolic health and obesity status.
| Hazard ratio | 95% confidence interval |
| ||
| Upper | Lower | |||
| Model 1 | ||||
| Age | 1.034 | 1.012 | 1.058 | 0.003 |
| Gender | 0.744 | 0.393 | 1.408 | 0.363 |
| Alanine aminotransferase | 1.008 | 1.005 | 1.011 | <0.01 |
| Serum creatinine | 0.663 | 0.216 | 2.039 | 0.474 |
| Total cholesterol | 1.006 | 1.002 | 1.009 | 0.001 |
| High-sensitivity C-reactive protein | 1.116 | 0.902 | 1.381 | 0.311 |
| Skeletal muscle index | 1.919 | 0.561 | 6.569 | 0.299 |
| Percent body fat | 1.934 | 0.599 | 6.238 | 0.270 |
| Systolic blood pressure | 1.004 | 0.995 | 1.012 | 0.387 |
| Groups by metabolic health and obesity | ||||
| MHNO | 1.000 | - | - | <0.01 |
| MHO | 1.338 | 0.670 | 2.672 | 0.410 |
| MUHNO | 4.321 | 2.702 | 6.910 | <0.01 |
| MUHO | 5.994 | 3.561 | 10.085 | <0.01 |
| Model 2† | ||||
| Age | 1.040 | 1.017 | 1.064 | 0.001 |
| Gender | 0.694 | 0.367 | 1.311 | 0.260 |
| Alanine aminotransferase | 1.009 | 1.006 | 1.012 | <0.01 |
| Serum creatinine | 0.564 | 0.181 | 1.756 | 0.323 |
| Total cholesterol | 1.006 | 1.002 | 1.009 | 0.001 |
| High sensitivity C-reactive protein | 1.143 | 0.911 | 1.435 | 0.248 |
| Skeletal muscle index | 2.157 | 0.642 | 7.248 | 0.214 |
| Percent body fat | 2.167 | 0.684 | 6.862 | 0.189 |
| Systolic blood pressure | 1.007 | 0.998 | 1.016 | 0.111 |
| Groups by metabolic health and obesity status | ||||
| MHNO | 1.000 | - | - | <0.01 |
| MHO | 1.385 | 0.694 | 2.765 | 0.356 |
| MUHNO | 4.458 | 2.790 | 7.122 | <0.01 |
| MUHO | 6.489 | 3.873 | 10.871 | <0.01 |
MHNO, metabolically healthy non-obese; MHO, metabolically healthy obese; MUHNO, metabolically unhealthy non-obese; MUHO, metabolically unhealthy obese.
* Additional adjustment for baseline history of smoking, alcohol drinking, regular exercise status, education and antihypertensive medication.
Additional adjustment for baseline history of smoking and education, and changes of body weight, alcohol drinking, regular exercise status and antihypertensive medication during the follow-up period.
Figure 2Disease-free survival by Kaplan-Meier analysis.
Median follow-up period was 48.7 months. Subjects were divided into four groups according to baseline metabolic health and obesity status.